Jennifer V. Grobelny

机构：Teva Pharmaceuticals (United States)

发表论文 10 篇 · 总被引 537 次 · h-index 7

代表论文

ALT-associated PML bodies are present in viable cells and are enriched in cells in the G2/M phase of the cell cycle (2000 · Journal of Cell Science · 被引 164)
SV40 infection induces telomerase activity in human mesothelial cells (2002 · Oncogene · 被引 119)
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity (2007 · Molecular Cancer Therapeutics · 被引 112)
Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway (2001 · Human Molecular Genetics · 被引 90)
2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines (2010 · Bioorganic & Medicinal Chemistry Letters · 被引 18)
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases (2008 · Bioorganic & Medicinal Chemistry Letters · 被引 16)